PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Both companies show declining cash positions (-2.60% vs AXSM's -11.73%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Below half of AXSM's -11.73%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-2.19%
0.75-0.9x AXSM's -2.67%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-4.69%
Below half AXSM's 12.98%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
Higher Long-Term Investments Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
≥ 1.5x AXSM's -0.85%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Similar yoy to AXSM's -2.21%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
28.73%
Less than half of AXSM's 200.55%. David Dodd sees a more disciplined AP approach or lower volume.
27.69%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
-27.69%
Less than half of AXSM's -85.75%. David Dodd sees fewer expansions in other current obligations.
27.28%
Less than half of AXSM's 60.18%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of AXSM's 3.33%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.72%
Less than half of AXSM's 22.20%. David Dodd sees far fewer liability expansions relative to competitor.
4.00%
Above 1.5x AXSM's 0.18%. Michael Burry suspects heavy new equity expansion or dilution.
-3.83%
Below half AXSM's -11.44%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
Below half AXSM's -30.38%. Michael Burry sees potential underperformance in building shareholder capital.
-2.25%
Similar yoy to AXSM's -2.21%. Walter Schloss sees parallel expansions in total capital.
0.67%
Higher Total Investments Growth compared to AXSM's zero value, indicating better performance.
-0.77%
Less than half of AXSM's 0.37%. David Dodd sees less overall debt expansion vs. competitor.
2.64%
Less than half of AXSM's 20.30%. David Dodd sees better deleveraging or stronger cash buildup than competitor.